The glycolytic pathway, also known as the EMP pathway (Embden-Meyerhof-Parnas pathway), refers to the degradation of glucose to pyruvate and the generation of ATP through a series of steps under anaerobic conditions, and glycolysis occurs in all living cells. It has been found that tumor cells preferentially choose the glycolytic pathway to provide energy even in the presence of oxygen, and the process is called aerobic glycolysis (Warburg effect). Tumor cells consume more glucose compared to normal cells, so by targeting areas that consume large amounts of glucose, cancer can be possibly identified. Targeting glycolysis in tumor cells is therefore expected to be an important therapeutic strategy for treating tumors.

TargetMol built the Glycolysis Compound Library that collected 555 active compounds targeting glycolysis-related compounds. The compounds in the library can be used in research relating to antitumor and glycolysis-related drug development.